6 results on '"Geng, Cuizhi"'
Search Results
2. An Analysis of Clinical and Pathologic Features, RecurIndex Genomic Profiles, and Survival Outcomes in HER2-Low Breast Cancer.
- Author
-
Hui, Tianli, Li, Sainan, Wang, Huimin, Ma, Xuejiao, Du, Furong, Gao, Wei, Yang, Shan, Sang, Meixiang, Li, Ziyi, Ding, Ran, Liu, Yueping, and Geng, Cuizhi
- Subjects
BREAST cancer prognosis ,THERAPEUTIC use of immunoglobulins ,THERAPEUTIC use of antineoplastic agents ,EPIDERMAL growth factor receptors ,CANCER relapse ,RETROSPECTIVE studies ,PROTEOMICS ,CANCER patients ,RISK assessment ,GENOMICS ,SURVIVAL analysis (Biometry) ,GENE expression profiling ,DESCRIPTIVE statistics ,RESEARCH funding ,TUMOR markers ,BREAST tumors - Abstract
Background: In recent years, breast cancer has become the most common cancer in the world, increasing women's health risks. Approximately 60% of breast cancers are categorized as human epidermal growth factor receptor 2 (HER2)-low tumors. Recently, antibody-drug conjugates have been found to have positive anticancer efficacy in patients with HER2-low breast cancer, but more studies are required to comprehend their clinical and molecular characteristics. Methods: In this study, we retrospectively analyzed the data of 165 early breast cancer patients with pT1-2N1M0 who had undergone the RecurIndex testing. To better understand HER2-low tumors, we investigated the RecurIndex genomic profiles, clinicopathologic features, and survival outcomes of breast cancers according to HER2 status. Results: First, there were significantly more hormone receptor (HR)-positive tumors, luminal-type tumors, and low Ki67 levels in the HER2-low than in the HER2-zero. Second, RI-LR (P =.0294) and RI-DR (P =.001) scores for HER2-low and HER2-zero were statistically significant. Third, within HER2-negative disease, HR-positive/HER2-low tumors showed highest ESR1, NFATC2IP, PTI1, ERBB2, and OBSL1 expressions. Fourth, results of the survival analysis showed that lower expression of HER2 was associated with improved relapse-free survival for HR-positive tumors, but not for HR-negative tumors. Conclusions: The present study highlights the unique features of HER2-low tumors in terms of their clinical characteristics as well as their gene expression profiles. HR status may influence the prognosis of patients with HER2-low expression, and patients with HR-positive/HER2-low expression may have a favorable outcome. In this study, the data of patients with early stage breast cancer who had undergone RecurIndex testing was analyzed. To better understand HER2-low tumors, genomic profiles, clinicopathologic features, and survival outcomes of breast cancers according to HER2 status were investigated. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. KIF20A is a Prognostic Marker for Female Patients with Estrogen Receptor-Positive Breast Cancer and Receiving Tamoxifen as Adjuvant Endocrine Therapy.
- Author
-
Huang, Xuchen, Li, Sainan, Gao, Wei, Shi, Jiajie, Cheng, Meng, Mi, Yunzhe, Liu, Yueping, Sang, Meixiang, Li, Ziyi, and Geng, Cuizhi
- Subjects
HORMONE receptor positive breast cancer ,PROGNOSIS ,HORMONE therapy ,WOMEN patients ,BREAST cancer ,TAMOXIFEN - Abstract
Purpose: Our aim was to verify whether KIF20A has the potential to serve as a prognostic marker for female patients with estrogen receptor (ER)-positive breast cancer (BC) and treated with tamoxifen (TAM).Patients and Methods: Online tools were used to investigate the potential correlation between KIF20A gene expression and survival of patients with ER-positive BC and TAM treatment. Furthermore, immunohistochemistry (IHC) was conducted to assess the expression levels of KIF20A in patients included from our center. The prognostic value of KIF20A for disease-free survival (DFS) and overall survival (OS) was further evaluated using Cox regression analysis.Results: According to the results obtained from online tools, it was found that patients with low KIF20A expression exhibited significantly better survival outcomes in terms of relapse-free survival (RFS), distant metastasis-free survival (DMFS), and OS compared to those with high KIF20A expression (P < 0.001, P < 0.001, and P = 0.008, respectively). Additionally, significantly lower gene expression of KIF20A was found in patients who responded to TAM than in those who did not respond to TAM (P < 0.001). We further included 203 patients with adjuvant TAM therapy, and IHC for KIF20A was performed on sections from paraffin-embedded blocks. Patients with low KIF20A expression had significantly better DFS and OS (P = 0.001 and 0.002, respectively, log rank test), and the expression of KIF20A was identified as an independent factor for predicting both DFS and OS (P = 0.001 and 0.008, respectively).Conclusion: KIF20A expression is an independent prognostic factor for survival in patients with ER-positive BC who received adjuvant TAM therapy. In clinical practice, IHC evaluation of KIF20A expression in surgical samples before administering tamoxifen may assist in predicting the treatment outcomes of these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Mucoepidermoid carcinoma of the breast
- Author
-
Cheng, Meng, Geng, Cuizhi, Tang, Tiantian, and Song, Zhenchuan
- Subjects
Adult ,Sentinel Lymph Node Biopsy ,Breast Neoplasms ,Middle Aged ,hormonal factors ,mucoepidermoid carcinoma ,Mastectomy, Modified Radical ,immunohistochemistry ,Humans ,Carcinoma, Mucoepidermoid ,Female ,Clinical Case Report ,prognosis ,breast ,Research Article ,Aged - Abstract
Rationale: Mucoepidermoid carcinoma (MEC) of the breast is a rare entity comprising specific morphological and immunohistochemical features, and has been previously only reported in 33 cases. Patient concerns: Four cases of MEC of the breast are reported in this study. All patients were women with ages ranging from 39 to 66 years. The lesions consisted of neoplastic solid nests and cystic spaces sometimes filled with mucoid material. Diagnoses: At high power, the tumors were composed of various proportions of basaloid, intermediate, epidermoid, and mucinous cells in different cases. All cases were classified as low-grade MEC of the breast. Tumor cells exhibited low levels of hormonal receptor expression in two cases (cases 1 and 3), and immunonegativity in one case (case 2). On the contrary, estrogen receptors (ER) were positively expressed in 60% of tumor cells in case 4. Tumor cells did not express human epidermal growth factor receptor 2 (HER-2)/neu protein in all the cases. Interventions: Modified radical mastectomy (Auchincloss) was performed in the first two cases, while the remaining two patients underwent mastectomy plus sentinel lymph node biopsy. Outcomes: All patients were alive and well without evidence of recurrent disease after a period ranging from 4 months to 156 months. Lessons: MEC of the breast is a rare primary carcinoma that is difficult to diagnose. Multiple tissue blocks are necessary before obtaining all cell types. Special stains for mucin and electron microscopy would be helpful in suspected cases. Hormonal factors might have an impact on the biological behavior of tumors, but further studies are needed to draw conclusions.
- Published
- 2017
5. Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018).
- Author
-
Xu, Binghe, Hu, Xichun, Feng, Jifeng, Geng, Cuizhi, Jin, Feng, Li, Hongyuan, Li, Man, Li, Qing, Liao, Ning, Liu, Donggeng, Liu, Jian, Liu, Qiang, Lu, Jinsong, Liu, Zhenzhen, Ma, Fei, Ouyang, Quchang, Pan, Yueyin, Shen, Kunwei, Sun, Tao, and Teng, Yuee
- Subjects
METASTATIC breast cancer ,BREAST cancer ,LOBULAR carcinoma ,SYMPTOMS ,CANCER ,DIAGNOSIS ,BREAST tumor treatment ,BREAST tumor diagnosis ,RESEARCH ,FERRANS & Powers Quality of Life Index ,RESEARCH methodology ,PROGNOSIS ,MEDICAL cooperation ,EVALUATION research ,MEDICAL protocols ,COMPARATIVE studies ,QUALITY of life - Abstract
Breast cancer is the most common malignant tumor among women in the world. In 2005, there were approximately 272,000 new cases diagnosed and more than 70,000 deaths from breast cancer in China. Of the patients who are newly diagnosed with breast cancer each year, approximately 3% to 10% have distant metastases at the time of diagnosis. Of those who have early stage disease at diagnosis, from 30% to 40% will develop advanced breast cancer. The 5-year survival rate for patients with advanced breast cancer is only 20%, and the median overall survival (OS) is 2 to 3 years. Although advanced breast cancer is still difficult to cure, physicians can relieve clinical symptoms, improve quality of life, and further prolong survival through the development of new drugs and the optimization model of treatment. Patients with advanced breast cancer have their own preferences in the choice of treatment options. Moreover, there is no standard recommendation for the treatment of refractory breast cancer after multiline therapy. To offer a reference for clinicians, a Chinese expert group has analyzed, summarized, and discussed related research data on the diagnosis, treatment, and prognosis of inoperable, locally advanced breast cancer and recurrent or metastatic breast cancer and has developed the Chinese expert consensus on the clinical diagnosis and treatment of advanced breast carcinoma (2018). [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
- Author
-
Xu, Binghe, Yan, Min, Ma, Fei, Hu, Xichun, Feng, Jifeng, Ouyang, Quchang, Tong, Zhongsheng, Li, Huiping, Zhang, Qingyuan, Sun, Tao, Wang, Xian, Yin, Yongmei, Cheng, Ying, Li, Wei, Gu, Yuanting, Chen, Qianjun, Liu, Jinping, Cheng, Jing, Geng, Cuizhi, and Qin, Shukui
- Subjects
- *
HER2 positive breast cancer , *HORMONE receptor positive breast cancer , *METASTATIC breast cancer , *LAPATINIB , *DRUG efficacy , *HAND-foot syndrome , *THERAPEUTIC use of antineoplastic agents , *QUINOLINE , *RESEARCH , *RESEARCH methodology , *CELL receptors , *ACRYLAMIDE , *PROGNOSIS , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *STATISTICAL sampling , *BREAST tumors , *LONGITUDINAL method - Abstract
Background: Despite therapeutic advances in HER2-positive metastatic breast cancer, resistance to trastuzumab inevitably develops. In the PHOEBE study, we aimed to assess the efficacy and safety of pyrotinib (an irreversible pan-HER inhibitor) plus capecitabine after previous trastuzumab.Methods: This is an open-label, randomised, controlled, phase 3 trial done at 29 hospitals in China. Patients with pathologically confirmed HER2-positive metastatic breast cancer, aged 18-70 years, who had an Eastern Cooperative Oncology Group performance status of 0 or 1, and had been previously treated with trastuzumab and taxanes were randomly assigned (1:1) to receive oral pyrotinib 400 mg or lapatinib 1250 mg once daily plus oral capecitabine 1000 mg/m2 twice daily on days 1-14 of each 21-day cycle. Randomisation was done via a centralised interactive web-response system with a block size of four or six and stratified by hormone receptor status and previous lines of chemotherapy for metastatic disease. The primary endpoint was progression-free survival according to masked independent central review. Efficacy and safety were assessed in all patients who received at least one dose of the study drugs. Results presented here are from a prespecified interim analysis. This study is registered with ClinicalTrials.gov, NCT03080805.Findings: Between July 31, 2017, and Oct 30, 2018, 267 patients were enrolled and randomly assigned. 134 patients received pyrotinib plus capecitabine and 132 received lapatinib plus capecitabine. At data cutoff of the interim analysis on March 31, 2019, median progression-free survival was significantly longer with pyrotinib plus capecitabine (12·5 months [95% CI 9·7-not reached]) than with lapatinib plus capecitabine (6·8 months [5·4-8·1]; hazard ratio 0·39 [95% CI 0·27-0·56]; one-sided p<0·0001). The most common grade 3 or worse adverse events were diarrhoea (41 [31%] in the pyrotinib group vs 11 [8%] in the lapatinib group) and hand-foot syndrome (22 [16%] vs 20 [15%]). Serious adverse events were reported for 14 (10%) patients in the pyrotinib group and 11 (8%) patients in the lapatinib group. No treatment-related deaths were reported in the pyrotinib group and one sudden death in the lapatinib group was considered treatment related.Interpretation: Pyrotinib plus capecitabine significantly improved progression-free survival compared with that for lapatinib plus capecitabine, with manageable toxicity, and can be considered an alternative treatment option for patients with HER2-positive metastatic breast cancer after trastuzumab and chemotherapy.Funding: Jiangsu Hengrui Medicine and National Key R&D Program of China.Translations: For the Chinese translation of the abstract see Supplementary Materials section. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.